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Aims The aim of this study was to determine whether growth differentiation factor-15 (GDF-15) predicts mortality and
morbidity after cardiac resynchronization therapy (CRT). Growth differentiation factor-15, a transforming growth
factor-b-related cytokine which is up-regulated in cardiomyocytes via multiple stress pathways, predicts mortality
in patients with heart failure treated pharmacologically.
Methods
and results
Growth differentiation factor-15 was measured before and 360 days (median) after implantation in 158 patients with
heart failure [age 68+11 years (mean+SD), left ventricular ejection fraction (LVEF) 23.1+9.8%, New York Class
Association (NYHA) class III (n ¼ 117) or IV (n ¼ 41), and QRS 153.9+28.2 ms] undergoing CRT and followed up
for a maximum of 5.4 years for events. In a stepwise Cox proportional hazards model with bootstrapping, adopting
log GDF-15, log NT pro-BNP, LVEF, and NYHA class as independent variables, only log GDF-15 [hazard ratio (HR),
3.76; P ¼ 0.0049] and log NT pro-BNP (HR, 2.12; P ¼ 0.0171) remained in the ﬁnal model. In the latter, the bias-cor-
rected slope was 0.85, the optimism (O) was 20.06, and the c-statistic was 0.74, indicating excellent internal validity.
In univariate analyses, log GDF-15 [HR, 5.31; 95% conﬁdence interval (CI), 2.31–11.9; likelihood ratio (LR) x
2 ¼ 14.6;
P , 0.0001], NT pro-BNP (HR, 2.79; 95% CI, 1.55–5.26; LR x
2 ¼ 10.4; P ¼ 0.0004), and the combination of both
biomarkers (HR, 7.03; 95% CI, 2.91–17.5; LR x
2 ¼ 19.1; P , 0.0001) emerged as signiﬁcant predictors. The bio-
marker combination was associated with the highest LR x
2 for all endpoints.
Conclusion Pre-implant GDF-15 is a strong predictor of mortality and morbidity after CRT, independent of NT pro-BNP. The
predictive value of these analytes is enhanced by combined measurement.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
The beneﬁts of cardiac resynchronization therapy (CRT) for
patients with heart failure are well established.
1,2 Predicting mor-
tality and morbidity on the basis pre-implant assessments,
however, remains a challenge. Numerous echocardiographic
measures of dyssynchrony have been explored,
3 but none has
emerged as a predictor of outcome in multicentre studies.
4
Increasing interest is being focused on the role of biomarkers in
theriskstratiﬁcationofpatientswithcardiacdisease.
5Growthdiffer-
entiation factor-15 (GDF-15), which is a member of the transform-
ing growth factor-b (TGF-b) cytokine superfamily,
6,7 has been
implicated in the regulation of cell survival, proliferation, and
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injury.
8 Alterations in TGF-bs have been observed in association
with atherosclerosis
9 and in patients who are at risk of coronary
events.
8,10
In patients with heart failure, GDF-15 is an independent predictor
of mortality, adding prognostic information to that obtained from
New York Class Association (NYHA) class, left ventricular ejection
fraction (LVEF), and N-terminal pro-B-type natriuretic peptide (NT
pro-BNP)levels.
11 We soughttodeterminewhether GDF-15corre-
lates with mortality and morbidity in patients with moderate-to-
severe heart failure undergoing CRT. A secondary objective was to
determine whether GDF-15, either alone or in combination with
NTpro-BNP,relatestosymptomaticresponse.Ofparticularinterest
wasthe possiblevalue ofpre-implantGDF-15levels inrisk-stratifying
patientsundergoingCRT,overandaboveNTpro-BNP,andthemore
traditional prognostic markers.
Methods
Subjects
The study group consisted of patients with heart failure undergoing
CRT in a single centre, from June 2002 to February 2007. The last
follow-up visit was in February 2008. Over this period, 299 patients
underwent implantation. For logistical reasons, however, only patients
(n ¼ 165) who underwent a planned implantation on one given day of
the week (Thursday) were eligible for the study. Four patients declined
consent. There were three failed implants. A total of 158 patients were
included in the study. Three patients died before a clinical review was
undertaken. Complete baseline and follow-up biochemical data were
available in 117 patients.
The diagnosis of heart failure was made if symptoms were associated
with objective evidence of LV dysfunction on echocardiography. The
diagnosis of ischaemic cardiomyopathy was made if systolic dysfunction
was associated with a history of myocardial infarction
12 or if there was
angiographically documented coronary heart disease (.50% stenosis
in  1 coronary arteries). Late gadolinium enhancement cardiovascular
magnetic resonance was also used to distinguish between ischaemic
and non-ischaemic cardiomyopathy, according to Assomull et al.
13
Patients with LV dysfunction in combination with the ﬁnding of trans-
mural or subendocardial late gadolinium uptake were classiﬁed as
having ischaemic cardiomyopathy, whereas patients with LV dysfunc-
tion and no gadolinium uptake, patchy uptake, or mid-wall hyperen-
hancement were classiﬁed as having non-ischaemic cardiomyopathy.
The study, which conforms to the Declaration of Helsinki, was
approved by the local Ethics Committee.
Study design
Patients underwent pacemaker implantation during an elective admis-
sion or after stabilization during the course of an unplanned admission
for acute decompensated heart failure. Patients underwent a clinical
assessment on the day prior to implantation and at 1, 3, and every 6
months following pacemaker implantation. Clinical follow-up data
relates to the last available follow-up before death or the end of the
study period.
Clinical assessment
This included assessment of NYHA functional class, quality of life (Min-
nesota Living with Heart Failure questionnaire),
14 and a 6 min hall-walk
test.
15 Response to CRT was deﬁned as survival for 1 year without
heart failure hospitalizations, plus improvement by  1 NYHA
classes or by  25% in 6 min walking distance.
Echocardiography
Two-dimensional echocardiography was performed at baseline using
GE Systems 5 and 7 scanners with EchoPAC (General Electric World-
wide, Slough, UK). Planimetry of apical four-chamber views and Simp-
son’s equation were used to derive LV volumes. The frame at the
beginning of the QRS complex was used to estimate end-diastolic
volume, whereas the frame with the smallest ventricular area just
prior to mitral valve opening was used to estimate end-systolic volume.
Device therapy
Patients underwent transvenous biventricular pacemaker implantation
using standard techniques under local anaesthesia. In line with national
guidelines at the time of the study, no patient underwent implantation
of a CRT device with implantable cardioverter deﬁbrillator back-up.
Patients in sinus rhythm underwent transmitral Doppler-directed optim-
ization of atrioventricular delay
16 prior to discharge and at every sched-
uled visit thereafter. In view that V-V optimization had not yet gained
credence in clinical practice, we followed an empirical protocol for
patients who did not respond symptomatically to CRT. Four sympto-
matic non-responders were programmed to a V-V delay of 30 ms (LV
ﬁrst). If no symptomatic response was witnessed after 6 weeks, pro-
gramming was changed to LV pacing only. The pacing mode was set
to DDD, with an interventricular delay of 0–4 ms, depending on the
manufacturer. Back-up atrial pacing was set at 60 b.p.m. For patients in
atrial ﬁbrillation, the ventricular-triggered mode was programmed. All
patients in the study were programmed to a minimum rate of
60 b.p.m. Patients were entered into the study only after a successful
implantation and were followed up in a dedicated CRT clinic.
Endpoints
The clinical endpoints considered were the composite of cardiovascu-
lar mortality or an unplanned hospitalization for worsening heart
failure. The ﬁrst event was included in the analysis. The second end-
point considered was cardiovascular mortality, and the third, total
mortality. Cardiac transplantation was considered as a cardiovascular
death. Mortality data were collected through medical records, and
where appropriate, from interviews with patient’s caregivers. Infor-
mation regarding clinical outcome was collected by an investigator
who was blinded to all other study data.
Biochemical assays
Venous blood samples were collected at baseline and 360 days (median)
after implantation, separated by cool centrifugation and stored at
270
8C for analysis at the end of the follow-up period. Analytes were
measured in two batches, one for GDF-15 and one for NT pro-BNP.
The investigators were unaware of the results during the study.
Growth differentiation factor-15
The GDF-15 assay was constructed using antibodies (R&D Systems,
Abingdon, Oxfordshire, UK) which have been utilized by other
groups.
11,17 Mouse monoclonal antibodies (200 ng/100 mL) speciﬁc for
GDF-15 were coated on ELISA plates overnight at room temperature.
The plates were then blocked overnight using 10% foetal calf serum.
The following day, 10 mL plasma samples or standards were pipetted
into the wells with 100 mL of immunoassay buffer. Plates were incubated
overnight, and following washes the next day, 5 ng of biotinylated goat
antibody speciﬁc for GDF-15 in 100 mL of assay buffer was pipetted
into each well. Plates were incubated at room temperature on a plate
P.W.X. Foley et al. 2750shaker for 2 h and then bound biotinylated tracer antibody was detected
using methyl-acridinium ester-labelled streptavidin on a Dynex MLX
plate reader, with sequential injections of hydrogen peroxide in nitric
acid, and sodium hydroxide with cetyl-trimethyl ammonium bromide,
4 s apart, as described previously.
18 The light signal was integrated
over 1 s. The lower limit of detection was 2.55 pg/mL.
N-terminal pro-B-type natriuretic peptide
Analysis for NT pro-BNP was undertaken using a non-competitive
electro-chemiluminescence using the Elecsys 1010 analyzer (Roche
Diagnostics, Lewes, UK).
Statistical analysis
Continuous variables are expressed as mean+SD. Normality was
tested using the Shapiro–Wilk test. Variables which were not normally
distributed (GDF-15 and NT pro-BNP) were log-transformed for stat-
istical analyses. Comparisons between normally distributed continuous
variables were made using ANOVA with Scheffe’s F procedure for mul-
tiple comparisons. Categorical variables were analysed using x
2 tests and
Scheffe’s post hoc test. Changes in variables from baseline to follow-up
were analysed using paired t tests. Statistical analyses were undertaken
using the SPSS 13.0 (Chicago, IL, USA), JMP 5.1 (Cary, NC, USA), and
MedCalc (Mariakerke, Belgium) programs. The Harrel ‘Design’ package
version 2.1-1 in R
19 was used for bootstrapping and validation.
Sample size
At our centre, we had observed an annual cardiovascular mortality
rate of 7% in 240 patients undergoing CRT. An arbitrary value of 2.0
was adopted as a clinically meaningful hazard ratio (HR) for GDF-15
as a predictor of cardiovascular mortality after CRT. A Cox regression
of the log HR on a covariate with an SD of 1.40 times the mean, based
on a sample of 130, achieved 90% power at a 0.05 signiﬁcance level to
detect a regression coefﬁcient of 0.6931 (HR, 2.0), at an anticipated
annual event rate of 7%. An additional 30 patients were added to
this sample to allow for implantation failures and patients lost at
follow-up. Power calculations were undertaken using the PASS 2008
package (NCSS, Kaysville, UT, USA).
Development and validation of the prediction model
According to Harrell et al.’s
20,21 recommendations on multivariate
prognostic modelling, no more than m/10 parameters were con-
sidered, where m is the number of uncensored events, in this case car-
diovascular deaths (n ¼ 40). In accordance with Harrell et al.’s
20,21
recommendations on multivariable prognostic modelling, variables
were selected on the basis of their proven clinical, pathophysiological,
and epidemiological relevance to the endpoint in question. As the
purpose of this study was to explore whether GDF-15, alone or in
combination with NT pro-BNP, predicts mortality in the study
cohort, these variables were included in the analyses. Two more vari-
ables, namely NYHA class and LVEF, were also chosen on the basis of
evidence showing inverse correlations between both NYHA class and
LVEF, and mortality in patients with heart failure.
22 Linearity assump-
tions were checked using Martingale residuals. The proportional
hazards assumption was checked using Schoenfeld
23 residuals. Vali-
dation of the Cox proportional hazards models was implemented
using bootstrapping.
20,21,24 For each group of the bootstrap samples,
the model was reﬁtted and tested against the observed sample in
order to derive an estimate of the predictive accuracy and bias. The
following parameters were derived: (i) the b coefﬁcients from Cox
proportional hazards models; (ii) Somer’s D rank correlation index,
and (iii) an estimate of the slope shrinkage.
20 The apparent Somer’s
D (Dapp) was derived using stepwise Cox proportional analyses. The
bootstrap-corrected performance of the predictor equation, or ‘opti-
mism’,
21 was quantiﬁed by assessing the difference between Somer’s D
in the original sample (Dorig) and D in the bootstrap sample (Dboot).
The average optimism, termed O, was derived by repeating the
above steps 500 times over. The bootstrap-corrected performance
of the original stepwise model, Dapp2 O, is, effectively, an honest esti-
mate of internal validity.
21
Kaplan–Meier survival curves were constructed for GDF-15 and NT
pro-BNP and statistical signiﬁcance was tested using the log-rank test.
Cut-off values for these variables were those which, on receiver-
operator characteristic curves, were found to have the highest
product of the sensitivity and speciﬁcity in relation to the endpoint
of cardiovascular mortality at the end of the study. The estimate of
the conﬁdence interval (CI) for the cut-off was calculated using the
sensitivity and speciﬁcity estimates. We applied error propagation
assuming statistical independency of speciﬁcity and sensitivity. Local
slopes d(cut-off)/d(sensitivity) and d(cut-off)/d(speciﬁcity) around the
optimal cut-off were obtained by linear regression. Slopes obtained
were multiplied by the CI for sensitivity and speciﬁcity, respectively.
To determine the predictive accuracy of GDF-15 and NT pro-BNP
over the follow-up period, we adopted the approach suggested by
Heagerty and Zheng.
25 This involved calculation of the AUCs and
the associated 90% CI as a measure of predictive accuracy at 1, 2,
and 3 years for each endpoint and for each biomarker. Linear predic-
tions were based on a Cox proportional hazards model.
Calculation of the combined biomarker index
The combined biomarker index was expressed as the sum of the pro-
ducts of the variables and their b coefﬁcients, or weights, identiﬁed in
the ﬁnal stepwise multivariable Cox proportional hazards model:
20,21
jb1x1 þ b2x2 þ ... þ bnxnj, where b1, b2,...,bn are the b coefﬁcients
for each variable and x1, x2,...,xn are the absolute values for each of
the variables. Thus, the combined biomarker index using the b coefﬁ-
cients from the ﬁnal bootstrapped Cox proportional hazards model
was calculated as follows: [0.7533   NT pro-BNP (pg/mL] þ
[(1.3257   GDF-15 (ng/L)].
Results
The characteristics of the study group are shown in Table 1.A s
shown in Table 2, signiﬁcant improvements in NYHA class, 6 min
walking distance, and quality-of-life scores were observed (P ,
0.0001). Response to CRT, deﬁned as survival for 1 year without
hospitalizations for heart failure plus improvement by  1 NYHA
classes or a 25% in 6 min walking distance, was 72%.
Growth differentiation factor-15 and
survival
After a maximum follow-up period of 1958 days (median 950
days), 40 (25%) patients died from cardiovascular causes (including
1 heart transplantation) and 11 from non-cardiovascular causes. A
total of 52 (33%) patients reached the composite endpoint of car-
diovascular mortality or heart failure hospitalization.
The utility of NT pro-BNP and GDF-15 in predicting the
various endpoints was assessed using Kaplan–Meier analyses. As
shown in Figure 1, a GDF-15  2720 ng/L (95% CI: 1983 and
3545 ng/L) was associated with a higher risk of cardiovascular
mortality, cardiovascular mortality or hospitalization for heart
failure, and total mortality (all P , 0.0001). The ability of this
cut-off of GDF-15 to discriminate between the risk groups was
GDF-15 and CRT 2751comparable to NT pro-BNP at a cut-off of 3170 pg/mL (95% CI:
1596 and 6763 pg/mL). Combining GDF-15 and NT pro-BNP
resulted in a signiﬁcant split between the risk groups with
respect to the cardiovascular mortality, total mortality, and the
composite endpoint of cardiovascular mortality or hospitalizations
for heart failure (Figure 2). Analysis of the AUCs over 1, 2, and 3
years for each endpoint and for GDF-15, NT pro-BNP, and the
combined biomarker score revealed that their predictive accuracy
remained stable over time. Cox proportional models predicted
outcome up to 3 years accurately and in a stable fashion (data
not shown).
Derivation and validation of predictive risk model
The objective in predictive modelling was to determine whether
GDF-15, in isolation or in combination with NT pro-BNP, pre-
dicted cardiovascular mortality in the whole cohort. A stepwise
Cox proportional hazards model with bootstrapping was used to
assess the ability of biomarkers to reliably predict cardiovascular
mortality. In a stepwise model adopting log GDF-15, log NT
pro-BNP, LVEF, and NYHA class as independent variables, only
log GDF-15 [HR, 3.76; coefﬁcient, 1.33; standard error (SE),
0.47; z-score, 2.80; P ¼ 0.0049] and log NT pro-BNP (HR, 2.12;
coefﬁcient, 0.75; SE, 0.32; z-score, 2.38; P ¼ 0.0171) remained in
the ﬁnal model. In this model, the bias-corrected slope was 0.85,
the optimism (O) was 20.06, and the c-statistic was 0.74.
Univariate analyses
Univariate Cox proportional hazards analyses were undertaken in
order to compare NT pro-BNP and GDF-15 to other variables
22,26
which are known to be of value in predicting mortality in patients
with heart failure (Table 3). In univariate Cox proportional hazards
analyses adopting cardiovascular mortality as the dependent
variable, log GDF-15 was associated with a HR of 5.31 (95% CI,
2.31–11.9; LR x
2 ¼ 14.6; P , 0.0001), compared with a HR of
2.79 (95% CI, 1.55–5.26; LR x
2 ¼ 10.4; P ¼ 0.0004) for
log NT pro-BNP and a HR of 7.03 (95% CI, 2.91–17.5; LR x
2 ¼
19.1; P , 0.0001) for the combined biomarker index. Importantly,
the latter was associated with the highest LR x
2.
In univariate Cox proportional hazards analyses adopting cardio-
vascular mortality or heart failure hospitalizations as the dependent
variable, log GDF-15 was associated with a HR of 3.77 (95% CI,
1.75–7.90; LR x
2 ¼ 11.0; P ¼ 0.0009), compared with a HR of
2.40 (95% CI, 1.46–4.08; LR x
2 ¼ 12.5; P ¼ 0.0004) for NT
pro-BNP and a HR of 4.93 (95% CI, 2.27–10.9; LR x
2 ¼ 16.3; P ¼
0.0001) for the combined biomarker index. Again, the combined
biomarker score was associated with the highest LR x
2.
In univariate Cox proportional hazards analyses adopting total
mortality as the dependent variable, log GDF-15 was associated
with a HR of 5.59 (95% CI, 2.69–11.4; LR x
2 ¼ 19.9; P ,
0.0001), compared with a HR of 4.30 (95% CI, 2.43–7.97; LR
x
2 ¼ 28.2; P , 0.0001) for NT pro-BNP and a HR of 10.5 (95%
CI, 4.74–24.1; LR x
2 ¼ 34.3; P , 0.0001) for the combined bio-
marker index. The combined biomarker score was therefore
associated with the highest LR x
2 for total mortality.
Two patients derived a symptomatic beneﬁt from a V-V delay of
30 ms (LV ﬁrst) and one patient derived a symptomatic beneﬁt
from LV pacing only. Two patients derived a symptomatic
beneﬁt from a V-V delay of 30 ms (LV ﬁrst) and one patient
derived a symptomatic beneﬁt from LV pacing only. Exclusion of
these patients in the analyses made no difference in the relation-
ship between GDF-15 or NT pro-BNP and the various mor-
tality/morbidity endpoints.
................................................................................
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Table 2 Clinical variables at baseline and follow-up
P-value
NYHA class
Baseline 3.3 (0.4)
Follow-up 2.1 (0.9) ,0.0001
6 min walk test (m)
Baseline 236.6 (115.2)
Follow-up 312.0 (120.1) ,0.0001
Quality-of-life scores
Baseline 53.5 (19.9)
Follow-up 34.2 (23.6) ,0.0001
Responders, n (%) 72%
P-values refer changes from baseline.
................................................................................
................................................................................
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Table 1 Characteristics of the study group
All
N 158
Age (years) 68.3+10.7
Male gender, n (%) 131 (83)
NYHA class 3.3+0.4
Ischaemic cardiomyopathy, n (%) 114 (72)
Atrial rhythm, n (%)
Sinus rhythm 122 (77)
Atrial ﬁbrillation 36 (23)
Co-morbidity, n (%)
Diabetes mellitus 28 (18)
Hypertension 43 (27)
CABG 34 (22)
NT pro-BNP (pg/mL) 3476.8+4098.6
GDF-15 (ng/L) 3838.7+4081.9
Medication, n (%)
Loop diuretics 144 (91)
ACE-inhibitors or ARBs 147 (93)
Beta-blockers 93 (59)
Spironolactone 73 (46)
ECG and echocardiography
QRS duration (ms) 153.9+28.2
LVEF (%) 23.1+9.8
Continuous variables are expressed as mean+SD. NYHA, New York Heart
Association class; CABG, coronary artery bypass grafting; ACE,
angiotensin-converting enzyme; ARBs, angiotensin II receptor blockers.
P.W.X. Foley et al. 2752Growth differentiation factor-15 and
N-terminal pro-B-type natriuretic
peptide changes after cardiac
resynchronization therapy
As shown in Figure 3, pre-implant NT pro-BNP and GDF-15 levels,
in isolation and together as a combined biomarker index, were
higher in non-responders. With respect to changes from baseline,
only the combination, reﬂected in the combined biomarker index,
showed a signiﬁcant reduction (Figure 4).
Discussion
As a member of the TGF-b cytokine superfamily,
6,7 GDF-15 has a
number of effects on cardiomyocyte biology. Recent evidence
Figure 1 Kaplan–Meier survival curves for elevations in growth differentiation factor-15 and N-terminal pro-B-type natriuretic peptide in
relation to outcome.
GDF-15 and CRT 2753suggests that it has autocrine and endocrine functions, such as
antagonizing the hypertrophic response and loss of ventricular per-
formance.
27 Although GDF-15 is not normally expressed in the
healthy adult myocardium, a dramatic induction of expression
occurs following injury, hypoxia, and cytokine/growth factor stimu-
lation.
28 Accordingly, high circulating levels of GDF-15 are
observed in conditions such as heart failure. Amidst the current
interest in risk-stratifying patients with heart failure undergoing
Figure 2 Kaplan–Meier survival curves for elevations in growth differentiation factor-15 and N-terminal pro-B-type natriuretic peptide in
relation to outcome, using dichotomous variables.
P.W.X. Foley et al. 2754CRT, we have shown that pre-implant levels of GDF-15 are a
strong predictor of long-term mortality following CRT device
implantation, independent of NT pro-BNP and other factors that
are known to be of prognostic value in patients with heart
failure. Furthermore, we have shown that the combination of
these analytes provides a better risk stratiﬁcation than each
analyte in isolation. Reductions in a combined biomarker index
were also witnessed in responders to CRT.
In the present study of patients undergoing CRT, GDF-15 was a
strong independent predictor of total mortality. These ﬁndings are
consistent with those of Kempf et al.
11 in patients with heart failure
treated pharmacologically. In the present study, GDF-15 also
emerged as a powerful predictor of cardiovascular mortality and
the composite endpoint of cardiovascular mortality or hospitaliz-
ations for heart failure. Furthermore, it was comparable or
superior to NT pro-BNP with respect to some of the endpoints.
With regard to cardiovascular mortality, for example, the LR x
2
from univariate Cox proportional hazards models were 14.6 for
GDF-15 and 10.4 for NT pro-BNP. The LR x
2 for GDF-15 was
also higher than that for NT pro-BNP with respect to the compo-
site endpoint of cardiovascular mortality or heart failure hospital-
izations or the endpoint of total mortality.
It is apparent from our analyses that combined biomarker index
is superior to either GDF-15 or NT pro-BNP alone in risk strati-
ﬁcation. In this respect, the LR x
2 associated with the combined
biomarker index as was as high as 19.1 for cardiovascular mortality,
16.3 for the combined endpoint of cardiovascular mortality or
heart failure hospitalizations, and 34.3 for total mortality. This indi-
cates that the combination of pre-implant GDF-15 and NT
pro-BNP is particularly useful in deﬁning a high-risk group of
patients after CRT.
We have found that changes in either GDF-15 or NT pro-BNP
after CRT were not predictive of clinical response. This might be
expected from the very high biological variability of these analytes.
In a study of 43 patients with stable heart failure assessed within 1
week, on consecutive days, and at weekly intervals over a 6-week
period, serial change values of 32%, 74%, and 113% for within-day,
Figure 3 Box-and-whisker plot for pre-implant growth differ-
entiation factor-15 and N-terminal pro-B-type natriuretic
peptide in relation to response or non-response to cardiac resyn-
chronization therapy. The ﬁve horizontal lines represent the 10th,
25th, 50th, 75th, and 90th percentiles, from bottom to top. For
calculation of the combined biomarker index, see text.
............................................
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Table 3 Univariate Cox proportional hazards
analyses of candidate predictors of cardiovascular
mortality in patients with heart failure undergoing
cardiac resynchronization therapy
Univariate
HR (95% CI) LR x
2 P-value
Age 1.03 (1.00–1.06) 2.48 0.0914
Female gender 0.24 (0.06–0.99) 3.9 0.0483
Ischaemic aetiology 1.56 (0.72–3.40) 1.28 0.2580
NYHA class 2.79 (1.49–5.23) 10.4 0.0013
Creatinine 1.01 (1.00–1.02) 4.15 0.0417
Log NT pro-BNP 2.79 (1.55–5.26) 12.4 0.0004
Log GDF-15 5.31 (2.31–11.9) 14.6 0.0001
Log combined biomarker
index
7.03 (2.91–17.5) 19.1 ,0.00001
QRS duration 1.00 (0.99–1.01) 0.25 0.6181
Atrial ﬁbrillation 0.99 (0.47–2.08) 0.00 0.9752
LVEF 0.96 (0.93–0.99) 5.51 0.0189
Medication
Diuretic 0.73 (0.22–2.38) 0.28 0.6146
ACE-I or ARA 1.34 (0.47–3.76) 0.30 0.5848
Beta-blockers 1.77 (0.94–3.35) 3.17 0.0751
Spironolactone 0.98 (0.52–1.83) 0.01 0.9368
LR x
2, likelihood ratio chi-squared.
GDF-15 and CRT 2755day-to-day, and week-to-week sampling were observed.
29
In healthy individuals, percentage serial change values of up to
92% for NT pro-BNP have been described.
30 Such high biological
variability is likely to hamper the use of changes in NT pro-BNP for
guiding clinical management. Although the day-to-day variation of
GDF-15 has not been explored, the case is likely to be similar to
that of NT pro-BNP, thus limiting its use in isolation as a predictor
of clinical beneﬁt. Importantly, however, the combined biomarker
index was higher in non-responders.
Limitations of the study
This study has several limitations. First, biomarkers were assessed
at baseline and at a median of 360 days after CRT. The time
required for CRT to have its full therapeutic effect has not been
ascertained and therefore, it is possible that a longer time period
is required for biomarkers to decrease following implantation. Sec-
ondly, the temporal variability of plasma levels of GDF-15 has not
been established, either in this study population or in patients with
heart failure who are not treated with CRT. Thirdly, this study was
undertaken in patients undergoing CRT without deﬁbrillator
back-up. Our ﬁndings may not apply to patients undergoing CRT
with deﬁbrillator back-up. Although we have established that
GDF-15 is a good prognostic biomarker in patients with advanced
heart failure undergoing CRT, it does not appear to be a good bio-
marker for identifying symptomatic responders to this therapy. Its
clinical application is therefore limited. To be conﬁdent on the
accuracy of the predictive model described herein, external vali-
dation is required.
Conclusions
Pre-implant GDF-15 levels are strong predictors of poor long-term
outcome after CRT, independent of NT pro-BNP, QRS duration,
and LVEF. In terms of relative risk, combined elevations in
GDF-15 and NT pro-BNP carry a particularly high risk of mortality
and morbidity after CRT. At a time when pre-implant echocardio-
graphy has failed to prove useful in risk-stratifying patients under-
going CRT,
4 further studies should focus on the possible value of
pre-implant GDF-15 levels, alone or in combination with NT
pro-BNP, in tailoring device therapy.
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